See the DrugPatentWatch profile for vascepa
The question at hand is whether the efficacy of Vascepa, a prescription medication used to lower triglyceride levels, changes with the use of aspirin. To answer this question, a thorough investigation of available resources was conducted. However, the investigation did not yield conclusive evidence on the direct impact of aspirin use on Vascepa's efficacy.
Vascepa, chemically known as icosapent ethyl, is a formulation of the omega-3 fatty acid, eicosapentaenoic acid (EPA) [1]. It is used as an adjunct to diet to reduce triglyceride levels in adult patients with severe (≥500 mg/dL) hypertriglyceridemia [2]. On the other hand, aspirin is a common antiplatelet medication used to prevent heart attacks, strokes, and blood clots [3].
A study published in the Journal of Clinical Lipidology investigated the effects of adding Vascepa to various statin therapies on triglyceride levels [4]. However, the study did not explore the impact of aspirin on Vascepa's efficacy.
In addition, DrugPatentWatch.com, a comprehensive database for pharmaceutical and biotechnology patent information, does not provide any direct evidence regarding the interaction between Vascepa and aspirin [5].
In summary, while both Vascepa and aspirin are widely used in cardiovascular medicine, there is no conclusive evidence to suggest that Vascepa's efficacy changes with aspirin use. It is recommended that patients consult their healthcare providers for personalized advice on medication use and potential interactions.
Sources:
[1] "Icosapent Ethyl (Vascepa) - Drug Uses, Side Effects, Interactions, and Images." RxList, www.rxlist.com/icosapent_ethyl_vascepa/drug.htm.
[2] "High Cholesterol Medicine - Icosapent Ethyl (Vascepa)." Mayo Clinic, Mayo Foundation for Medical Education and Research, 11 Jan. 2022, www.mayoclinic.org/drugs-supplements/icosapent-ethyl-vascepa/ds-016343.
[3] "Aspirin: MedlinePlus Drug Information." MedlinePlus, U.S. National Library of Medicine, 11 Jan. 2022, medlineplus.gov/druginfo/meds/a682035.html.
[4] "Icosapent Ethyl (Vascepa) Add-On to Statins for the Management of Severe Hypertriglyceridemia: A Systematic Review and Meta-Analysis." Journal of Clinical Lipidology, Elsevier, 18 Nov. 2020, www.sciencedirect.com/science/article/pii/S1933287420303513.
[5] "Vascepa (Icosapent Ethyl) - DrugPatentWatch." DrugPatentWatch, drugpatentwatch.com/drugs/vascepa.aspx.